---
title: "Daily Hong Kong Stock Market News Briefing (April 3, Thursday)"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/234302012.md"
description: "1. Dazhu CNC is researching the overseas issuance of H shares and listing. \n2. WuXi AppTec sold 50.8 million shares, with a transaction amount of approximately HKD 2.178 billion. \n3. HSBC downgraded the rating of China Southern Airlines H shares to reduce holdings, with a target price of HKD 3. \n4. Tencent repurchased HKD 17.1 billion in the first quarter. \n5. Alibaba repurchased 51 million shares in the first quarter, with a remaining repurchase quota of USD 20.1 billion. \n6. CSTONE PHARMA plans to place 80 million shares at a placement price of HKD 2.933, with a net amount estimated at HKD 232 million. \n7. HENLIUS's anti-VEGF monoclonal antibody clinical study reached its primary endpoint"
datetime: "2025-04-03T01:09:05.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/234302012.md)
  - [en](https://longbridge.com/en/news/234302012.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/234302012.md)
generator: "portal-rs"
---

# Daily Hong Kong Stock Market News Briefing (April 3, Thursday)

1.  Dazhu CNC: Research and demonstration of the issuance of overseas securities (H shares) and listing matters.

2.  WuXi AppTec (02359.HK): Sold 50.8 million shares of WuXi AppTec, accounting for approximately 4.23% of the total share capital, with a transaction amount of approximately HKD 2.178 billion.

3.  HSBC downgraded the H share rating of China Southern Airlines (01055.HK) to reduce holdings, with a target price of HKD 3.

4.  Tencent Holdings (00700.HK): Repurchased HKD 17.1 billion in the first quarter, exceeding the level of the same period last year.

5.  Alibaba (09988.HK): Repurchased a total of 51 million ordinary shares at a total price of USD 600 million in the first quarter, with an remaining repurchase quota of USD 2.01 billion under the board-authorized share repurchase plan as of March 31, 2025.

6.  CSTONE PHARMA (02616.HK): Plans to place a total of 80 million placement shares at a placement price of HKD 2.933 per share, with estimated net proceeds of HKD 232 million, 90% of which will be used for assets in the group's "Pipeline 2.0".

7.  HENLIUS (02696.HK): The phase III clinical study of the recombinant anti-VEGF humanized monoclonal antibody injection HLX04-O for the treatment of wet age-related macular degeneration (wAMD) achieved its primary research endpoint

### Related Stocks

- [02616.HK](https://longbridge.com/en/quote/02616.HK.md)
- [02696.HK](https://longbridge.com/en/quote/02696.HK.md)
- [603259.CN](https://longbridge.com/en/quote/603259.CN.md)
- [02359.HK](https://longbridge.com/en/quote/02359.HK.md)
- [600029.CN](https://longbridge.com/en/quote/600029.CN.md)
- [01055.HK](https://longbridge.com/en/quote/01055.HK.md)
- [TCTZF.US](https://longbridge.com/en/quote/TCTZF.US.md)
- [TCEHY.US](https://longbridge.com/en/quote/TCEHY.US.md)
- [00700.HK](https://longbridge.com/en/quote/00700.HK.md)
- [301200.CN](https://longbridge.com/en/quote/301200.CN.md)
- [02268.HK](https://longbridge.com/en/quote/02268.HK.md)

## Related News & Research

- [Shanghai Henlius Added to Hong Kong Stock Connect Eligible Securities List](https://longbridge.com/en/news/298164593.md)
- [WuXi AppTec files HKEX next-day disclosure return, issues 875,080 H shares on convertible bond conversion](https://longbridge.com/en/news/298423295.md)
- [WuXi AppTec files HKEX next-day disclosure return, issues 6,321,703 H shares on convertible bond conversion](https://longbridge.com/en/news/298285562.md)
- [WuXi AppTec files HKEX next-day disclosure return, issues 5,137,325 H shares on convertible bond conversion at HKD 153 each](https://longbridge.com/en/news/298187482.md)
- [WuXi AppTec files HKEX next-day disclosure return reporting 6,827,131 new H shares from bond conversion](https://longbridge.com/en/news/298010654.md)

---
> **Disclaimer: This article is for reference only and does not constitute any investment advice.**